

Posttranslational Modifications

International Edition: DOI: 10.1002/anie.201604058
German Edition: DOI: 10.1002/ange.201604058

Synthesis and Macrodomein Binding of Mono-ADP-Ribosylated Peptides

Hans A. V. Kistemaker⁺, Aurelio Pio Nardoza⁺, Herman S. Overkleef, Gijs A. van der Marel, Andreas G. Ladurner,* and Dmitri V. Filippov*

Abstract: Mono-ADP-ribosylation is a dynamic posttranslational modification (PTM) with important roles in signaling. Mammalian proteins that recognize or hydrolyze mono-ADP-ribosylated proteins have been described. We report the synthesis of ADP-ribosylated peptides from the proteins histone H2B, RhoA and, HNP-1. An innovative procedure was applied that makes use of pre-phosphorylated amino acid building blocks. Binding assays revealed that the macrodomains of human MacroD2 and TARG1 exhibit distinct specificities for the different ADP-ribosylated peptides, thus showing that the sequence surrounding ADP-ribosylated residues affects the substrate selectivity of macrodomains.

PTMs play key roles in signaling and protein–ligand interactions. They usually occur through the reversible modification of one or more amino acids. Adenosine diphosphate ribosylation (ADP-ribosylation) is a PTM associated with DNA damage, apoptosis, and gene regulation.^[1] ADP-ribosylation involves the enzymatic transfer of ADP-ribose (ADPr) from β -NAD⁺ to the side chain of amino acids.^[1a,2] Numerous ADP-ribosyltransferases (ARTs),^[3] including bacterial toxins, mono-ADP-ribosylate (MARylate) acceptor proteins.^[4] MARylation is also a starting point for poly-ADP-ribosylation (PARylation).^[2] Recently, new mono-ARTs have been characterized that function in human diseases.^[5] The

mechanisms and functions of MARylation are considerably less well understood compared to poly-ADP-ribosylation.^[6]

The human MacroD1, MacroD2, and TARG1 proteins contain a macrodomain capable of “reading” and “erasing” MARylation.^[7] Currently, the only known substrates are ADP-ribosylated ARTD1 and MARylated GSK3 β , ARTD10, or ARTD1^{E988Q}. The basis of substrate selectivity of these mono-ADP-ribosylhydrolases is not known.

To facilitate the analysis of MARylation, we synthesized MARylated peptides (ADPr peptides) and investigated their binding to different macrodomains. Our pioneering studies on the synthesis of ADPr peptides revealed that the “on-resin” formation of a phosphomonoester, which is the precursor of the pyrophosphate, was an inefficient step.^[8] Therefore, we decided to develop pre-phosphorylated amino acid building blocks to remove this bottleneck. First, we attempted the synthesis of a histone H2B peptide with ADP-ribosylation of Glu2.^[9] Although the synthesis of a phosphoribosylated glutamic acid building block was accomplished, solid-phase synthesis of an N-terminal tetrapeptide of H2B could not be completed owing to side reactions initiated by migration of the 1-*O*-glutamyl moiety (see the Supporting Information). Therefore, we turned to the H2B N terminus (**19** and **20**, Scheme 2) MARylated at glutamine, which is resistant to acyl migration and hydrolysis.^[8] The MARylation sites from RhoA (Asn41;^[10] **21**, Scheme 2) and human neutrophil defensin 1 (HNP-1; Arg14;^[11] **22**, Scheme 2) were also targeted. Citrulline (Cit) was selected as an isostere for arginine (Arg14). We used citrulline since we expected native arginine to be troublesome as a result of the very high basicity of its side chain and the extremely poor solubility of arginine derivatives with a free guanidino group in organic solvents.

First, we synthesized protected ribosylated amino acids (see **4** in Scheme 1).^[12] For the synthesis of ribosylated Asn and Cit, we used donor **1** and TBSOTf as an activator (Scheme 1). The ribosylation of Asn proceeded in an α -selective manner ($\alpha/\beta = 97:3$, 79%). Ribosylation of the less reactive Cit with donor **1** proceeded less selective ($\alpha/\beta = 78:22$, 40%). Next, the 4-methoxybenzyl ethers (PMB) were acidolyzed (HCl/HFIP).^[12,13] No anomerization was observed for **2** (Asn) but **3** anomerized ($\alpha/\beta = 46:54$) during PMB deprotection. Subsequent bis-acetylation yielded compounds **5** and **6** in good yields, and silica gel chromatography enabled separation of the individual anomers. We then cleaved the 5'-*O*-silyl ether and introduced the protected phosphate.^[14] The TIPS group in **4** (Gln)^[12] was cleaved with Et₃N-3HF and the TBDPS group in compounds **5** and **6** was removed using HF-pyridine. Alcohols **7** and **8** were obtained in good yields as pure α -anomers. In contrast, alcohol **9** was obtained as

[*] H. A. V. Kistemaker,^[†] Prof. Dr. H. S. Overkleef, Prof. Dr. G. A. van der Marel, Dr. D. V. Filippov
Leiden Institute of Chemistry, Dept. of Bio-organic Synthesis
Leiden University, Einsteinweg 55, 2333 CC Leiden (The Netherlands)

E-mail: filippov@chem.leidenuniv.nl

Homepage: <http://biosyn.lic.leidenuniv.nl/>

Dr. A. P. Nardoza,^[†] Prof. Dr. A. G. Ladurner
Department of Physiological Chemistry, Biomedical Center
Faculty of Medicine, Ludwig-Maximilians-Universität München
Großhaderner Street 9, 82152 Planegg-Martinsried (Germany)

Prof. Dr. A. G. Ladurner
Center for Integrated Protein Science Munich (CIPSM)

Ludwig-Maximilians-Universität München
Butenandt Street 5, 81377 Munich (Germany)

and
Munich Cluster for Systems Neurology (SyNergy)


Ludwig-Maximilians-Universität München
Feodor Lynen Street 17, 81377 Munich (Germany)

E-mail: andreas.ladurner@med.lmu.de

Homepage: <http://www.ladurnerlab.de/>

[†] These authors contributed equally to this work.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under <http://dx.doi.org/10.1002/anie.201604058>.




Scheme 1. Synthesis of phosphoribosylated glutamine **13**, asparagine **14**, and citrulline **15**. a) TBSOTf, CH₂Cl₂/dioxane and Fmoc-Asn-OBn or Fmoc-Cit-OBn, -10 °C; b) i. HCl, HFIP; ii. Ac₂O, Py; c) Et₃N·(HF)₃, Py (for compound **4**), HF-pyridine, Py (for compound **5** and **6**); d) i. (tBuO)₂PN(iPr)₂, 1-Me-Im·HCl (0.3 M), 1-Me-Im (0.2 M), DMF; ii. tBuOOH; e) H₂, Pd/C, tBuOH/dioxane/H₂O. TBSOTf = *tert*-butyldimethylsilyl trifluoromethanesulfonate, HFIP = hexafluoroisopropanol, 1-Me-Im·HCl = 1-methylimidazolium chloride, 1-Me-Im = 1-methylimidazole; Py = pyridine, DMF = *N,N*-dimethylformamide.

anomeric mixture ($\alpha/\beta = 34:66$), while α -configured **6** was used as starting compound. The phosphotriester was installed through phosphorylation of **7**, **8**, and **9** with di-*tert*-butyl *N,N*-diisopropylphosphoramidite and subsequent oxidation.^[14] This procedure yielded the di-*tert*-butyl-protected phosphates **10**, **11**, and **12** with minimal formation of H-phosphonate byproducts. Ribosylated Cit (**12**) was obtained as a mixture of anomers, which could be separated by silica gel chromatography. Finally, the benzyl esters in **10**, **11**, and **12** were removed by hydrogenolysis to afford **13**, **14**, and **15**. Since anomerization occurred during the hydrogenation of **12** (Cit), building block **15** was used as an anomeric mixture ($\alpha/\beta = 62:38$) in the following solid-phase synthesis. We note that native ADPr arginine is also configurationally unstable and spontaneously forms a mixture of anomers.^[15]

Tentagel resin equipped with the base-labile HMBA linker was selected as the most suitable for assembly of the acid-labile target peptides.^[8,16] Standard solid-phase methods were applied to synthesize the intermediate peptide **16** (Scheme 2), in which amino acids with reactive side chains were equipped with base-labile protecting groups (PG). Such a strategy had proved to be viable in the past for the synthesis of short ADPr peptides.^[8] For arginine, we opted for the allyloxycarbonyl (Alloc) group, which is compatible with nucleic acids and peptides.^[17] After completion of the peptide synthesis, the phosphotriester *tert*-butyl (tBu) protecting groups were removed using trifluoroacetic acid (TFA) in dichloromethane to yield **17**.^[14] However, ¹H-NMR of **19** revealed considerable anomerization ($\alpha/\beta = 65:35$). Therefore, we optimized the tBu cleavage using amino acid **10** as a test substrate (Table S1 in the Supporting Information). One equivalent of HCl in HFIP appeared to be most suitable.

Accordingly, resin **16** was shaken for one hour in the presence of one equivalent of HCl in HFIP, followed by a pyridine wash. “On-resin” analysis with ³¹P-NMR spectroscopy showed almost complete removal of the tBu groups, with trace amounts of mono-*tert*-butyl-protected phosphate. Successive treatment with HCl/HFIP for 30 minutes yielded intermediate **17**. Next, immobilized 5′-phosphoribosylpeptide **17** was reacted with adenosine phosphoramidite **18** with ETT as an activator.^[14,18] Oxidation of the intermediate P^{III}-P^V species (with CSO) followed by cyanoethyl cleavage (with DBU) afforded protected ADPr peptides **19–22**. Next, the Alloc (Arg) and Dmab^[19] (Glu and Asp) groups in protected **21** and **22** were removed by using Pd(PPh₃)₄ and hydrazine, respectively. Finally, ADPr peptides were cleaved from the resin using saturated ammonia in TFE,^[16] which also removed most of the remaining protecting groups. An NH₃/TFE mixture proved superior to methanolic ammonia^[8] in terms of yield and provided peptide carboxamide as the only product. Addition of concentrated aqueous ammonia to the mixture ensured benzoyl removal from the adenosine-NH₂ to yield crude ADPr peptides **19–22**. A combination of reversed-phase (RP)-HPLC and boronate affinity chromatography^[20] was used to purify the products. Repeated lyophilization afforded pure **19** and **20** in 4% and 5% overall yield, respectively. ADPr peptides **21** and **22** were purified by anion-exchange chromatography to yield the products in 0.5% and 0.2% overall yield. Premature cleavage of the peptide from the solid support during hydrazine treatment is a likely reason for the lower yield.^[21] The anomeric purity of the obtained peptides was determined by ¹H-NMR. The α -anomeric configuration in peptides **19** and **21** was retained, while for peptide **20**, which was treated with TFA, a ratio of 65:35 (α/β)



Scheme 2. Synthesis of ADP-ribosylated peptides from histone H2B (**19**, **20**), RhoA (**21**), HNP-1 (**22**). a) Fmoc-amino acid-OH, HCTU, DIPEA, NMP; b) i. HCl, HFIP; ii. pyridine; c) i. ETT, **18**, acetonitrile; ii. CSO, acetonitrile; iii. DBU, acetonitrile; iv. NH₃, TFE; v. NH₄OH. TBDPS = *tert*-butyldiphenylsilyl, TIPS = triisopropylsilyl, HCTU = *N,N,N',N'*-tetramethyl-*O*-(6-chloro-1*H*-benzotriazol-1-yl)uronium hexafluorophosphate, DIPEA = diisopropylethylamine, NMP = *N*-methylpyrrolidine, ETT = 5-ethylthiotetrazole; CSO = (1*S*)-(1*+*)-(10-camphorsulfonyl)-oxaziridine, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, TFE = trifluoroethanol, HMBA = 4-hydroxymethyl benzoic acid linker.


was observed. Peptide **22** was also obtained as anomeric mixture ($\alpha/\beta = 60/40$). The peptides without ADPr modification (**19S–22S**) were synthesized using standard solid-phase peptide synthesis (SPPS; see the Supporting Information) and used as negative controls in our binding assays.

With the target peptides in hand, we established their affinity toward human MacroD2 and TARG1. MacroD2 and TARG1, both MARYlation readers and erasers, diverge in sequence. To ensure that the binding results not complicated by possible catalytic events, we used point mutants of MacroD2 and TARG1 [MacroD2^{G100E/I189R/Y190N} (referred to as MacroD2TM) and TARG1^{D125A}]. The catalytic activity of these mutants is impaired, while ADPr and MARYlated ARTD10 binding is retained.^[7a,c] We realize that the binding affinity of ADPr peptides containing isosteric replacements instead of native amino acids (Glu and Arg) may be different from the native counterparts. However, the difference is likely to be small, since the ADPr moiety recognized by all ADPr-binding macrodomains is identical in all cases. Even if the presence of an amine instead of a carbonyl group was to change the affinity by 0.2–2 kcal mol⁻¹ (due to one more or one fewer hydrogen bonds, for example), then this would be unlikely to create a situation whereby all tested macrodomains have the same affinity and/or selectivity for distinct MARYlated synthetic peptides.

Where possible, we derived the thermodynamic parameters of the MacroD2 and TARG1 proteins for compounds **19**, **21**, **22** and for the negative controls **19S**, **21S**, and **22S** by using isothermal titration calorimetry (Figure 1 and the Supporting

Information). MacroD2TM binds peptide **19** with a K_D of 2.8 ± 0.8 μM, while TARG1^{D125A} shows no binding (Figure 1). This was confirmed using biotinylated ADPr H2B peptide **20** in a streptavidin pull-down (Figure S2 in the Supporting Information). In contrast, peptide **21** binds both macrodomains with similar affinity (180 ± 80 nM for MacroD2TM and 550 ± 90 nM for TARG1^{D125A}; Figure 1). Strikingly, the ADPr HNP-1 peptide **22** binds much better to TARG1^{D125A} compared to MacroD2TM. The TARG1^{D125A}-derived K_D value for peptide **22** is 150 ± 20 nM, whereas the affinity for MacroD2TM is about 16-fold lower at 2.4 ± 0.4 μM, and ADPr binds TARG1^{D125A} with an approximately 20-fold lower affinity at 2.6 μM (Figure 1).^[7a] Our results reveal distinct selectivities of MacroD2TM and TARG1^{D125A} toward ADPr peptides. Indeed, MacroD2TM binds all three tested peptides, irrespective of peptide sequence, length, and nature of the modified amino acid. This indicates that MacroD2TM tolerates diverse sequence contexts surrounding the ADP-ribosylated amino acid. MacroD2 thus either exhibits promiscuous binding toward ADPr substrates, or other mechanisms confer binding specificity on MacroD2 in vivo. In contrast, the amino acid context surrounding the ADPr amino acid strongly influences the binding of TARG1^{D125A} towards ADPr peptides, thus suggesting a more specific target range for TARG1 that will have to be tested in vivo. Our data reveal that macrodomains bind synthesized mono-ADP-ribosylated peptides and that the local sequence context surrounding MARYlation sites greatly affects the affinity of a given macrodomain for their PTM-modified target. The synthetic

A



B

Protein	Peptide	K_D (μ M)	ΔH (kcal/mol)	ΔG (kcal/mol)	$-T \Delta S$ (kcal/mol)	N
MacroD2 TM	Histone H2B peptide (19)	2.8 (0.8)	-22.7 (0.7)	-7.6 (0.1)	15 (0.7)	0.8 (0.07)
TARG1 ^{D125A}	Histone H2B peptide (19)			Not binding		
MacroD2 TM	RhoA peptide (21)	0.18 (0.03)	-13.9 (0.9)	-9.2 (0.08)	4.7 (0.8)	1 (0.06)
TARG1 ^{D125A}	RhoA peptide (21)	0.55 (0.09)	-10.6 (0.3)	-8.6 (0.1)	2.1 (0.4)	0.7 (0.01)
MacroD2 TM	HNP-1 peptide (22)	2.4 (0.4)	-27.5 (1.8)	-7.7 (0.1)	19.8 (1.9)	0.8 (0.03)
TARG1 ^{D125A}	HNP-1 peptide (22)	0.15 (0.02)	-14.5 (0.8)	-9.3 (0.1)	5.1 (0.9)	0.8 (0.02)
Protein	Ligand	K_D (μ M)	Reference			
MacroD2 TM	ADP ribose	0.55	G. Jankevicius et al., <i>Nat. Struct. Mol. Biol.</i> 2013 [7c]			
TARG1 ^{D125A}	ADP ribose	2.6	R. Sharifi et al., <i>EMBO J.</i> 2013 [7a]			

Figure 1. Binding affinity of the MacroD2 and TARG1 macrodomains with ADP-ribosylated histone H2B (19), RhoA (21), and HNP1 (22) peptides. A) Representative isothermal titration calorimetry (ITC) profiles for the titration of 19, 21, and 22 into a solution containing either MacroD2TM or TARG1^{D125A}. B) ITC data derived from the interaction measurements between the macrodomains and the ADP-ribosylated peptides. Data are given as the mean ($n=3$) \pm SEM (values in brackets).

method, which uses phosphoribosylated amino acids, gives entry to pure, well-defined ADPr peptides of biological relevance in amounts sufficient to study the emerging roles of MARylation in biological recognition and regulation.

Acknowledgements

We thank Gyula Timinszky for fruitful discussions and Christiane Kotthoff for experimental assistance. A.P.N. was the recipient of a Marie Curie Intra-European Fellowship for career development (MitoMAR, contract 627676, FP7-PEOPLE-2013-IEF). This research was financially supported by the Netherlands Organization for Scientific Research (NWO).

Keywords: ADP-ribosylation · peptides · posttranslational modifications · proteins · solid-phase synthesis

How to cite: *Angew. Chem. Int. Ed.* **2016**, *55*, 10634–10638
Angew. Chem. **2016**, *128*, 10792–10796

[1] a) P. O. Hassa, S. S. Haenni, M. Elser, M. O. Hottiger, *Microbiol. Mol. Biol. Rev.* **2006**, *70*, 789–829; b) K. W. Ryu, D. S. Kim, W. L. Kraus, *Chem. Rev.* **2015**, *115*, 2453–2481.

[2] a) G. Demurcia, J. Jongstrabilen, M. E. Ittel, P. Mandel, E. Delain, *EMBO J.* **1983**, *2*, 543–548; b) H. Juarezsalinas, V. Levi, E. L. Jacobson, M. K. Jacobson, *J. Biol. Chem.* **1982**, *257*, 607–609; c) M. Miwa, M. Ishihara, S. Takishima, N. Takasuka, M. Maeda, Z. Yamaizumi, T. Sugimura, S. Yokoyama, T. Miyazawa, *J. Biol. Chem.* **1981**, *256*, 2916–2921.

[3] M. O. Hottiger, P. O. Hassa, B. Luscher, H. Schuler, F. Koch-Nolte, *Trends Biochem. Sci.* **2010**, *35*, 208–219.

[4] a) D. Corda, M. Di Girolamo, *EMBO J.* **2003**, *22*, 1953–1958; b) G. Glowacki et al., *Protein Sci.* **2002**, *11*, 1657–1670.

[5] a) S. Vyas, P. Chang, *Nat. Rev. Cancer* **2014**, *14*, 502–509; b) S. Vyas, M. Chesarone-Cataldo, T. Todorova, Y. H. Huang, P. Chang, *Nat. Commun.* **2013**, *4*, 2240; c) E. S. Scarpa, G. Fabrizio, M. Di Girolamo, *FEBS J.* **2013**, *280*, 3551–3562; d) M. C. Haigis et al., *Cell* **2006**, *126*, 941–954; e) D. W. Koh et al., *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 17699–17704.

[6] a) A. K. L. Leung, *J. Cell Biol.* **2014**, *205*, 613–619; b) B. A. Gibson, W. L. Kraus, *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 411–424.

[7] a) R. Sharifi et al., *EMBO J.* **2013**, *32*, 1225–1237; b) F. Rosenthal et al., *Nat. Struct. Mol. Biol.* **2013**, *20*, 502–507; c) G. Jankevicius, M. Hassler, B. Golia, V. Rybin, M. Zacharias, G. Timinszky, A. G. Ladurner, *Nat. Struct. Mol. Biol.* **2013**, *20*, 508–514.

[8] G. J. van der Heden van Noort, M. G. van der Horst, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov, *J. Am. Chem. Soc.* **2010**, *132*, 5236–5240.

[9] a) N. Ogata, K. Ueda, O. Hayaishi, *J. Biol. Chem.* **1980**, *255*, 7610–7615; b) P. Adamietz, A. Rudolph, *J. Biol. Chem.* **1984**,

- 259, 6841–6846; c) L. O. Burzio, P. T. Riquelme, S. S. Koide, *J. Biol. Chem.* **1979**, 254, 3029–3037.
- [10] a) A. Sekine, M. Fujiwara, S. Narumiya, *J. Biol. Chem.* **1989**, 264, 8602–8605; b) S. Rösener, G. S. Chhatwal, K. Aktories, *FEBS Lett.* **1987**, 224, 38–42; c) I. Just, C. Mohr, G. Schallehn, L. Menard, J. R. Didsbury, J. Vandekerckhove, J. van Damme, K. Aktories, *J. Biol. Chem.* **1992**, 267, 10274–10280.
- [11] a) G. Paone, A. Wada, L. A. Stevens, A. Martin, T. Hirayama, R. L. Levine, J. Moss, *Proc. Natl. Acad. Sci. USA* **2002**, 99, 8231–8235; b) M. Castagnini, M. Picchianti, E. Talluri, M. Biagini, M. Del Vecchio, P. Di Procolo, N. Norais, V. Nardi-Dei, E. Balducci, *PLoS One* **2012**, 7, e41417; c) L. A. Stevens, R. L. Levine, B. R. Gochuico, J. Moss, *Proc. Natl. Acad. Sci. USA* **2009**, 106, 19796–19800.
- [12] H. A. V. Kistemaker, G. J. van der Heden van Noort, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov, *Org. Lett.* **2013**, 15, 2306–2309.
- [13] A. G. Volbeda, H. A. Kistemaker, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov, J. D. C. Codee, *J. Org. Chem.* **2015**, 80, 8796–8806.
- [14] H. A. V. Kistemaker, L. N. Lameijer, N. J. Meeuwenoord, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov, *Angew. Chem. Int. Ed.* **2015**, 54, 4915–4918; *Angew. Chem.* **2015**, 127, 4997–5000.
- [15] a) N. J. Oppenheimer, *J. Biol. Chem.* **1978**, 253, 4907–4910; b) N. J. Oppenheimer, *Methods Enzymol.* **1984**, 106, 399–403; c) J. Moss, N. J. Oppenheimer, R. E. West, Jr., S. J. Stanley, *Biochemistry* **1986**, 25, 5408–5414.
- [16] G. J. van der Heden van Noort, P. van Delft, N. J. Meeuwenoord, H. S. Overkleeft, G. A. van der Marel, D. V. Filippov, *Chem. Commun.* **2012**, 48, 8093–8095.
- [17] a) N. M. A. J. Kriek, N. J. Meeuwenoord, H. van den Elst, H. A. Heus, G. A. van der Marel, D. V. Filippov, *Org. Biomol. Chem.* **2006**, 4, 3576–3586; b) H. Kunz, C. Unverzagt, *Angew. Chem. Int. Ed. Engl.* **1984**, 23, 436–437; *Angew. Chem.* **1984**, 96, 426–427.
- [18] H. Gold, P. van Delft, N. Meeuwenoord, J. D. C. Codee, D. V. Filippov, G. Eggink, H. S. Overkleeft, G. A. van der Marel, *J. Org. Chem.* **2008**, 73, 9458–9460.
- [19] W. C. Chan, B. W. Bycroft, D. J. Evans, P. D. White, *J. Chem. Soc. Chem. Commun.* **1995**, 2209–2210.
- [20] J. L. Sims, H. Juarezsalinas, M. K. Jacobson, *Anal. Biochem.* **1980**, 106, 296–306.
- [21] This is because deprotection and cleavage using 0.1M NaOH in dioxane/MeOH for compound **21** resulted in a significantly higher yield (6%). However, the glycosidic linkage was also affected when using this method, resulting in a complex mixture of products, so this approach was dismissed.

Received: April 26, 2016

Revised: June 6, 2016

Published online: July 28, 2016